Contributed by Vic Simianu, MBA, Principal, Founder at Sphinx Str

Q. Specialty pharmacy continues to dominate healthcare headlines. Why is this segment so important right now?
Most healthcare leaders don’t realize that 80% of the drugs in the pipeline are IV-formulations with specialty indications, and that no pharmacies are getting access to the downstream oral versions if they can’t prove their capabilities or partner on launch today. I can’t emphasize this enough for providers that are still thinking about specialty or infusion — it is existential for pharmacy survival moving forward. Specialty patients represent a relatively small portion of the overall population, yet they drive a disproportionate share of drug spend and resource intensity across the healthcare system.

That reality changes the stakes. However, I won’t sugarcoat the reality that it is not easy to compete in this space. Everyday in this field, small operational breakdowns can create outsized consequences — lost margin, denied claims, strained payer relationships, audit vulnerability, limited-distribution access issues, and stalled growth. At the same time, organizations that build the right foundation can unlock meaningful enterprise value. That is why many pharmacy leaders are seeking experienced guidance early, before complexity turns into costly rework.

Q. What makes specialty and infusion pharmacy so different from traditional pharmacy operations?
Traditional pharmacy is often driven by prescription volume and dispensing efficiency. Specialty and infusion pharmacy are driven by infrastructure, coordination, and precision. These models require far more than filling prescriptions well.

Operators must navigate accreditation standards, payer and manufacturer expectations, multi-state licensure, infusion and nursing coordination, cold-chain and hazardous shipping protocols, clinical documentation, prior authorization workflows, inventory controls, referral capture, and increasingly sophisticated reporting requirements. Success depends on whether these moving parts are built into the operating model from the beginning. When organizations try to bolt them on later, growth often outpaces control.

Q. How do experienced consultants help organizations navigate that level of complexity?
The most effective advisors do more than provide recommendations. They help organizations translate strategy into execution across several interconnected areas: operations, financial performance, regulatory readiness, and market growth.

That may include designing accreditation-ready workflows, building scalable staffing models, assessing payer and trade strategy, evaluating service-line expansion opportunities, strengthening referral conversion processes, supporting multi-state compliance, and creating practical dashboards that connect daily performance to long-term financial goals. The best consulting support is not theoretical. It gives leadership a clearer roadmap, stronger controls, and measurable improvement in both revenue performance and risk reduction.

Q. At what stage in a pharmacy or infusion pharmacy’s growth journey is outside guidance most valuable?
Usually earlier than leaders think. The need often begins before launch, during expansion planning, ownership transition, specialty service-line development, infusion build-out, or entry into new payer and manufacturer relationships. It also becomes critical when a pharmacy is preparing for accreditation, scaling into multiple states, adding nursing or clinical programs, evaluating technology changes, or trying to improve profitability without sacrificing compliance.

Many organizations wait until there is a failed audit, payer friction, margin compression, staffing instability, or referral leakage. By then, the work is often more expensive and more disruptive. The strongest outcomes usually happen when leadership brings in experienced support during key inflection points, while there is still room to design intentionally rather than react defensively.

Q. What are the most common gaps that hold specialty and infusion pharmacies back?
A few patterns show up repeatedly. Outside of the reimbursement pressures and industry dynamics that affect all independents, one common gap is the lack of alignment between operations and financial modeling. Another is treating compliance as a separate function instead of embedding it into workflows, staffing, training, and reporting. This misunderstanding can lead to “operational diverticulitis” where credentialing, patient flow, documentation, inventory, contracting, and quality management all operate in silos instead of harmoniously.
There is also often a business development gap. Pharmacies may have strong clinical capability but weak referral strategy, inconsistent provider engagement, unclear value messaging, and very often, brutally limited analytics to demonstrate performance to partners. In a competitive environment, growth does not come from clinical excellence alone. It comes from pairing clinical credibility with operational discipline and commercial clarity.

Q. How does accreditation translate into profitability?
It’s existential. Accreditation is often the price of entry. It can influence access to payer participation, manufacturer relationships, limited-distribution opportunities, referral confidence, and broader market credibility. But accreditation alone does not create sustainable margin.

Profitability improves when accreditation standards are operationalized — meaning documentation, quality review, staff accountability, patient management, and audit readiness become part of the everyday workflow. When compliance is proactive instead of reactive, organizations reduce disruption, protect contracts, and create a more stable platform for growth. In that sense, accreditation is not just a regulatory milestone. It is a business enabler when it is tied to how the pharmacy actually runs.

Q. In today’s reimbursement environment, where does real ROI come from?
Real ROI comes from disciplined alignment. Alignment between reimbursement strategy and operational capability. Alignment between staffing and patient volume. Alignment between clinical documentation and payer expectations. Alignment between software systems and management visibility. Alignment between growth goals and regulatory readiness.

When those elements are disconnected, pharmacies leak value through preventable denials, missed referral opportunities, underperforming payer arrangements, inefficient labor models, poor inventory practices, and avoidable compliance risk. When they are aligned, organizations are positioned to improve cash flow, scale more confidently, and make smarter strategic decisions. That is often where seasoned financial and clinical operations guidance delivers the greatest value.

Q. What role do integrated software solutions play in a future-ready pharmacy model?
An increasingly central one. Specialty and infusion pharmacy leaders need more than isolated systems that handle individual tasks. They need integrated visibility across the business. That includes compliance tracking, credentialing and licensing oversight, workflow management, patient onboarding, referral analytics, staffing productivity, payer performance, and financial forecasting.

Without that visibility, leadership teams are often managing from lagging indicators and fragmented data. With the right systems and reporting structure in place, they can identify risk sooner, improve accountability, and make decisions with more confidence. Technology alone is not the solution, but when paired with strong operating design, it becomes a force multiplier.

Q. What does a future-ready specialty or infusion pharmacy look like?
It is compliant by design, financially disciplined, clinically credible, operationally scalable, and commercially intentional. It has the infrastructure to support multi-state growth, audit readiness, payer demands, and partner expectations without losing control of performance. It understands that specialty and infusion pharmacy are no longer just dispensing models; they are integrated care, access, and margin platforms.

The organizations that will stand out are the ones that combine clinical excellence with smart business architecture. They are not waiting for complexity to catch up with them. They are building systems, processes, and partnerships that allow them to grow responsibly and compete effectively.

Q. Any parting thoughts for leaders that are looking to grow in the space?
Seek some expert advice instead of thinking that you know it all. This space is changing rapidly and operators that stay stagnant or do not innovate will be constantly playing catch-up. If you operate in specialty or infusion pharmacy — whether as an independent pharmacy, infusion provider, health system, physician-affiliated operation, or investor-backed platform — the question is not whether complexity and industry pressures will increase. They will. The more important question is whether your organization has the operational structure, financial visibility, compliance discipline, business development strategy, and technology alignment to scale successfully. That takes smart investment in the right areas and partnerships.

Experienced advisory support can identify growth barriers, operational inefficiencies, compliance exposure, contracting opportunities, and infrastructure gaps before they become expensive problems. For leaders looking for measurable ROI, controlled expansion, and long-term sustainability, the strongest next step is often a strategic conversation with the right consultants who understand both the clinical and business realities of this market.